{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:38:35Z","timestamp":1792852715663,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtha.2025.03.026","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T02:26:32Z","timestamp":1744079192000},"page":"1774-1786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Direct oral anticoagulant failure in patients with venous thromboembolism\u2014why and what next?"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1374-7333","authenticated-orcid":false,"given":"Dawn","family":"Swan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Lerkevang","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jecko","family":"Thachil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.03.026_bib1","article-title":"Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis","volume":"366","author":"Khan","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2025.03.026_bib2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jtha.2023.09.020","article-title":"Anticoagulation in chronic kidney disease: current status and future perspectives","volume":"22","author":"Jones","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.026_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jtha.2023.01.002","article-title":"Dilemmas in hematology: consults in patients with arterial thrombosis","volume":"21","author":"Swan","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.026_bib4","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1016\/j.jtha.2023.06.017","article-title":"The prothrombotic tendency of metabolic-associated fatty liver disease","volume":"21","author":"Swan","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.026_bib5","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1161\/STR.0000000000000456","article-title":"Diagnosis and management of cerebral venous thrombosis: a scientific statement from the American Heart Association","volume":"55","author":"Saposnik","year":"2024","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.03.026_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14311","article-title":"Catheter-related deep vein thrombosis: where are we at and where are we going? Updates and ongoing unmet clinical needs","volume":"55","author":"Girardi","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jtha.2025.03.026_bib7","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1161\/CIR.0000000000001092","article-title":"Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association","volume":"146","author":"Levine","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.03.026_bib8","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib10","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1016\/S2352-3026(16)00023-5","article-title":"Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study","volume":"3","author":"Raskob","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.03.026_bib11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1055\/a-1171-0486","article-title":"How to differentiate recurrent deep vein thrombosis from postthrombotic syndrome","volume":"40","author":"Gautam","year":"2020","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2025.03.026_bib12","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1055\/a-2341-6349","article-title":"Use of magnetic resonance direct thrombus imaging for the diagnostic management of suspected thrombosis in routine clinical practice","volume":"8","author":"de Jong","year":"2024","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2025.03.026_bib13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.amjmed.2009.09.037","article-title":"Silent pulmonary embolism in patients with deep venous thrombosis: a systematic review","volume":"123","author":"Stein","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archinte.160.2.159","article-title":"Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis","volume":"160","author":"Meignan","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034778","article-title":"Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies","volume":"10","author":"Salmasi","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtha.2025.03.026_bib16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00228-015-1983-z","article-title":"Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation","volume":"72","author":"Forslund","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.03.026_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-065700","article-title":"Comparison of medication adherence to different oral anticoagulants: population-based cohort study","volume":"13","author":"Ingason","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtha.2025.03.026_bib18","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1185\/03007995.2015.1096242","article-title":"Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the pharmacy quality alliance measure","volume":"31","author":"McHorney","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jtha.2025.03.026_bib19","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1007\/s12325-022-02391-z","article-title":"Venous thromboembolism recurrence among patients who abandon oral anticoagulant therapy in the USA: a retrospective longitudinal study","volume":"40","author":"Alberts","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtha.2025.03.026_bib20","doi-asserted-by":"crossref","first-page":"7943","DOI":"10.1002\/cam4.4307","article-title":"Trends in patient-reported outcome use in early phase dose-finding oncology trials - an analysis of ClinicalTrials.gov","volume":"10","author":"Lai\u2013Kwon","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib21","article-title":"Reasons for nonadherence to the direct oral anticoagulant apixaban: a cross-sectional survey of atrial fibrillation patients","volume":"2","author":"Tarn Derjung","year":"2023","journal-title":"JACC Adv"},{"key":"10.1016\/j.jtha.2025.03.026_bib22","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/rth2.12316","article-title":"Self-reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants","volume":"4","author":"Toorop","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.026_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1185\/03007995.2014.978939","article-title":"Packaging interventions to increase medication adherence: systematic review and meta-analysis","volume":"31","author":"Conn","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jtha.2025.03.026_bib24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00228-021-03212-y","article-title":"Prevalence, contributory factors and severity of medication errors associated with direct-acting oral anticoagulants in adult patients: a systematic review and meta-analysis","volume":"78","author":"Al Rowily","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.03.026_bib25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11239-016-1465-x","article-title":"Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)","volume":"43","author":"Hakeam","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.03.026_bib26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.amjmed.2016.12.033","article-title":"Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance","volume":"130","author":"Martin","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0091270006286904","article-title":"Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.03.026_bib28","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/jth.12973","article-title":"Of men and meals","volume":"13","author":"Beyer-Westendorf","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.026_bib29","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/jcph.1097","article-title":"Regional gastrointestinal absorption of apixaban in healthy subjects","volume":"58","author":"Byon","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.03.026_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.intf.2024.100007","article-title":"Anticoagulation and antiplatelet therapy in short bowel syndrome: a systematic review","volume":"1","author":"Mercer","year":"2024","journal-title":"Intestinal Failure"},{"key":"10.1016\/j.jtha.2025.03.026_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1052053","article-title":"Feasibility, effectiveness, and safety of edoxaban administration through percutaneous endoscopic gastrostomy: 12-months follow up of the ORIGAMI study","volume":"9","author":"Cappannoli","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/8755122516646384","article-title":"Administration of direct oral anticoagulants through enteral feeding tubes","volume":"32","author":"Peterson","year":"2016","journal-title":"J Pharm Technol"},{"key":"10.1016\/j.jtha.2025.03.026_bib33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa","volume":"55","author":"Parasrampuria","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2025.03.026_bib34","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.soard.2018.08.025","article-title":"The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study","volume":"14","author":"Kr\u00f6ll","year":"2018","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.jtha.2025.03.026_bib35","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.soard.2021.12.023","article-title":"The APB study: apixaban pharmacokinetics in bariatric patients before to 1 year after vertical sleeve gastrectomy or Roux-en-Y gastric bypass","volume":"18","author":"Steele","year":"2022","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.jtha.2025.03.026_bib36","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.thromres.2017.11.006","article-title":"The effect of bariatric surgery on direct-acting oral anticoagulant drug levels","volume":"163","author":"Rottenstreich","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.03.026_bib37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/bloodadvances.2021006696","article-title":"Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery","volume":"7","author":"Kushnir","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.03.026_bib38","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/pharmaceutics14030662","article-title":"Absorption of direct oral anticoagulants in cancer patients after gastrectomy","volume":"14","author":"Puhr","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jtha.2025.03.026_bib39","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jth.15823","article-title":"Direct oral anticoagulants after bariatric surgery\u2014what is the evidence?","volume":"20","author":"Leong","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.026_bib40","first-page":"342.e17","article-title":"Personalized anticoagulation: guided apixaban dose adjustment to compensate for pharmacokinetic abnormalities related to short-bowel syndrome","volume":"34","author":"Pollak","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jtha.2025.03.026_bib41","first-page":"79","article-title":"Venous thromboembolism in patients with inflammatory bowel disease: review of literature and practical algorithms","volume":"84","author":"Coremans","year":"2021","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.jtha.2025.03.026_bib42","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cgh.2019.12.043","article-title":"Shedding light on hemostasis in patients with inflammatory bowel diseases","volume":"19","author":"Lagrange","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jtha.2025.03.026_bib43","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/MEG.0000000000001084","article-title":"Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease","volume":"30","author":"Lobo","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jtha.2025.03.026_bib44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.phrs.2018.07.016","article-title":"Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)","volume":"135","author":"Gelosa","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jtha.2025.03.026_bib45","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.3390\/ijms22168531","article-title":"The clinical significance of drug-food interactions of direct oral anticoagulants","volume":"22","author":"Grze\u015bk","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtha.2025.03.026_bib46","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cpt.1845","article-title":"Pharmacoepidemiologic screening of potential oral anticoagulant drug interactions leading to thromboembolic events","volume":"108","author":"Zhou","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2025.03.026_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100137","article-title":"Drug-drug interactions between direct oral anticoagulants and anticonvulsants and clinical outcomes: a systematic review","volume":"7","author":"Candeloro","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.026_bib48","article-title":"from the American Heart Association Electrocardiography & Arrhythmias Committee of the Council of Clinical Cardiology. Drug interactions affecting oral anticoagulant use","volume":"15","author":"Mar","year":"2022","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jtha.2025.03.026_bib49","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1055\/s-0043-1762596","article-title":"Drug-drug interactions in the treatment of cancer-associated venous thromboembolism with direct oral anticoagulants","volume":"50","author":"Hellfritzsch","year":"2024","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.03.026_bib50","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtha.2025.03.026_bib51","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/rheumatology\/keab416","article-title":"Characteristics of purified anti-\u03b22GPI IgG N-glycosylation associate with thrombotic, obstetric and catastrophic antiphospholipid syndrome","volume":"61","author":"Liu","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jtha.2025.03.026_bib52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/antib13010021","article-title":"Diagnosis and management of catastrophic antiphospholipid syndrome and the potential impact of the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"13","author":"Jacobs","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.jtha.2025.03.026_bib53","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/cei\/uxae079","article-title":"Antibody profiles in the mosaic of \u2018seronegative\u2019 APS syndrome","volume":"218","author":"Truglia","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jtha.2025.03.026_bib54","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/1358863X16668588","article-title":"Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: findings from RE-COVER, RE-COVER II, and RE-MEDY","volume":"21","author":"Goldhaber","year":"2016","journal-title":"Vasc Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib55","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.03.026_bib56","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin k antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib57","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.03.026_bib58","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.03.026_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.03.026_bib60","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/bjh.19635","article-title":"BSH Committee. Guidelines on the investigation and management of antiphospholipid syndrome","volume":"205","author":"Arachchillage","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.03.026_bib61","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.03.026_bib62","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtha.2025.03.026_bib63","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/jth.14935","article-title":"Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Zuily","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.026_bib64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13075-021-02702-9","article-title":"The presence of non-criteria manifestations negatively affects the prognosis of seronegative antiphospholipid syndrome patients: a multicenter study","volume":"24","author":"da Rosa","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jtha.2025.03.026_bib65","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/hematology.2024000544","article-title":"Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease","volume":"2024","author":"Salter","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2025.03.026_bib66","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.3390\/jcm13144191","article-title":"Antiphospholipid syndrome: insights into molecular mechanisms and clinical manifestations","volume":"13","author":"Celia","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1144229","article-title":"Endothelial dysfunction and immunothrombosis in sepsis","volume":"14","author":"Maneta","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2025.03.026_bib68","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1055\/s-0043-1771268","article-title":"Are antiphospholipid antibodies a surrogate risk factor for thrombosis in sepsis?","volume":"50","author":"Thachil","year":"2024","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.03.026_bib69","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018917","article-title":"Direct oral anticoagulants in patients with inherited thrombophilia and venous thromboembolism: a prospective cohort study","volume":"9","author":"Campello","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2025.03.026_bib70","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1182\/bloodadvances.2024012611","article-title":"Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia","volume":"8","author":"Cohen","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.03.026_bib71","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/JBM.S344083","article-title":"Apixaban use in patients with protein c and s deficiency: a case series and review of literature","volume":"13","author":"Al Sulaiman","year":"2022","journal-title":"J Blood Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib72","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.thromres.2021.04.002","article-title":"Thrombotic storm under DOAC treatment in a patient with homozygous antithrombin Budapest III mutation","volume":"201","author":"Condoluci","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.03.026_bib73","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1016\/j.jtha.2024.08.006","article-title":"The use of direct oral anticoagulants in the secondary prevention of venous thromboembolism in patients with severe thrombophilia: communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia","volume":"22","author":"Kovac","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.026_bib74","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/rheumatology\/40.6.652","article-title":"Thrombosis in Beh\u00e7et's disease: a retrospective survey from a single UK centre","volume":"40","author":"Ames","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jtha.2025.03.026_bib75","article-title":"Thrombosis in vasculitis: an updated review of etiology, pathophysiology, and treatment","volume":"10","author":"Zhu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jtha.2025.03.026_bib76","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10067-007-0685-z","article-title":"Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation","volume":"27","author":"Ahn","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jtha.2025.03.026_bib77","article-title":"Lessons learned from a case of Behcet's disease presenting with fever and life-threatening venous thromboembolism","volume":"14","author":"Conlon","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jtha.2025.03.026_bib78","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtha.2025.03.026_bib79","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/14782715221134720","article-title":"Challenges in managing patients on anticoagulation: thrombocytopenia, resumption after bleeding and recurrent thrombosis","volume":"52","author":"Swan","year":"2022","journal-title":"J R Coll Physicians Edinb"},{"key":"10.1016\/j.jtha.2025.03.026_bib80","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2 V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"Guglielmelli","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtha.2025.03.026_bib81","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.03.026_bib82","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.03.026_bib83","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1111\/jth.15438","volume":"19","author":"Moore","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.026_bib84","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1365-2141.2007.06679.x","article-title":"Recurrent venous thromboembolism during coumarin therapy. Data from the computerised registry of patients with venous thromboembolism","volume":"138","author":"Lobo","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.03.026_bib85","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.03.026_bib86","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.03.026_bib87","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.03.026_bib88","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtha.2025.03.026_bib89","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/ATVBAHA.123.318779","article-title":"Updates in the incidence, pathogenesis, and management of cancer and venous thromboembolism","volume":"43","author":"Girardi","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2025.03.026_bib90","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s10930-015-9628-8","article-title":"The proteolytic profile of human cancer procoagulant suggests that it promotes cancer metastasis at the level of activation rather than degradation","volume":"34","author":"Kee","year":"2015","journal-title":"Protein J"},{"key":"10.1016\/j.jtha.2025.03.026_bib91","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.19414","article-title":"Cancer-associated venous thrombosis in adults (second edition): a British Society for Haematology Guideline","volume":"205","author":"Alikhan","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.03.026_bib92","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib93","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2025.03.026_bib94","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib95","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib96","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib97","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib98","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/a-1486-7497","article-title":"Failure of the Ottawa Score to predict the risk of recurrent venous thromboembolism in cancer patients: the prospective PREDICARE cohort study","volume":"122","author":"Girard","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.026_bib99","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.thromres.2019.07.005","article-title":"The Ottawa score performs poorly in cancer patients with incidental pulmonary embolism","volume":"181","author":"Mulder","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.03.026_bib100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2023.02.003","article-title":"Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism","volume":"112","author":"Vedovati","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jtha.2025.03.026_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109184","article-title":"Predictors of recurrent venous thromboembolism and major bleeding in patients with cancer: a secondary analysis of the CANVAS trial","volume":"244","author":"Uno","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.03.026_bib102","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/jth.15235","article-title":"The timing of venous thromboembolism in ovarian cancer patients: a nationwide Danish cohort study","volume":"19","author":"Str\u00f8m Kahr","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.026_bib103","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejogrb.2013.06.004","article-title":"Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival","volume":"170","author":"Abu Saadeh","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jtha.2025.03.026_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102546","article-title":"Dual direct oral anticoagulant therapy in challenging thrombosis: a case series","volume":"8","author":"Chornenki","year":"2024","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625002065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625002065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T02:11:06Z","timestamp":1780279866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625002065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":104,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1538783625002065"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.03.026","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulant failure in patients with venous thromboembolism\u2014why and what next?","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}